Abstract
Background:Cytochrome p450 is the main drug metabolic pathway mostly by CYPIIIA4 and CYPIID6 enzymes. The second one is the responsible for the clearance from 20% of most common drugs as paracetamol or codeine and presented four different metabolizer phenotype: normal metabolizer (NM), intermediate metabolizer (IM), poor metabolizer (PM) or ultra‐rapid metabolizer (UM). CYP2D6 (MIM∗608902) is a highly polymorphic gene that encodes CYPIID6. The different metabolizer capabilities are caused by different alleles on CYP2D6 due to entire gene deletions or duplications or 19 SNPs. This is the pathway to metabolize one of the Gaucher disease (GD) treatments, which dose administration is regulated according to the metabolizer phenotype being this one of the administration limitationsAims:With this background we consider interesting stablish the metabolizer and allelic frequency from CYP2D6 on our GD population and compare it with the general Spanish population and a Gaucher disease patients cohort.Methods:We select 109 type 1 GD patients genetically confirmed and we used the xTAG®CYP2D6 kit to identify the CYP2D6 gene alleles. This group was compared with a control group obtained from the completed Spanish reports on the pharmagkb database and with a worldwide type 1 GD patients enrolled on the ENCORE trial. Statistical significance was considered if p‐value<0.05Results:As a result, 87 patients were classified as normal, 14 as intermediate, 6 as poor and 2 as ultra‐rapid metabolizers. The allelic frequencies were 5.5% for duplication and 4.5% for deletion. The most common allele was wild type and the second one was the null allele ∗4. Alleles ∗6, ∗9 and ∗35 presented a higher frequency than expected. There was no relationship between the patients’ gender or GBA1 genotype and the allelic or phenotypic frequencies on CYPIID6 enzyme and CYP2D6 gene. This results were different than expected for Spanish population but agrees with the ENCORE Gaucher cohort.Summary/Conclusion:To sum up, our Spanish GD series shows an unexpected distribution of alleles that encode for an enzyme with a reduced or absent activity than the results previously reported in the Spanish population. This is important due to the pharmacological interactions and the impact of unexpected secondary effect that can be higher on this population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.